ADAR ELISA Kit (Human) (OKEH07654)

Catalog No: OKEH07654

Size:96T

Product Info

• Predicted Species Reactivity: Homo sapiens, Human
• Application: Enzyme-linked Immunosorbent assay-Sandwich
• ELISA Kit Detection Method: Colorimetric, OD450 nm
• ELISA Kit Linearity:

  Sample	1:2	1:4	1:8	1:16
  serum(n=5)	109-118% (n = 20)	113-123% (n = 20)	99-109% (n = 20)	106-116% (n = 20)
  EDTA plasma(n=5)	85-95% (n = 20)	104-115% (n = 20)	103-111% (n = 20)	94-105% (n = 20)
  heparin plasma(n=5)	103-112% (n = 20)	107-117% (n = 20)	109-120% (n = 20)	81-90% (n = 20)

• ELISA Kit Principle: Aviva Systems Biology ADAR ELISA Kit (Human) (OKEH07654) is based on standard sandwich enzyme-linked immuno-sorbent assay technology. An antibody specific for ADAR has been pre-coated onto a 96-well plate (12 x 8 Well Strips) and blocked. Standards or test samples are added to the wells, incubated and removed. A biotinylated detector antibody specific for ADAR is added, incubated and followed by washing. Avidin-Peroxidase Conjugate is then added, incubated and unbound conjugate is washed away. An enzymatic reaction is produced through the addition of TMB substrate which is catalyzed by HRP generating a blue color product that changes yellow after adding acidic stop solution. The density of yellow coloration read by absorbance at 450 nm is quantitatively proportional to the amount of sample ADAR captured in well.
• ELISA Kit Range: 0.312-20ng/mL
• ELISA Kit Recovery: Mean recovery when spiking into sample matrices at concentrations within the dynamic range: 90% (n = 20)
• ELISA Kit Reproducibility: Mean Intra-assay CV%: <=8.9% (n = 20)
  Mean Inter-assay CV%: <=9.3% (n = 20)
• ELISA Kit Component:
  • ADAR Microplate: 96 Wells (12 x 8 Well strips)
  • ADAR Lyophilized Standard: 2
  • 100X Biotinylated ADAR Detector Antibody: 1 x 120 uL
  • 100X Avidin-HRP Conjugate: 1 x 120 uL
  • Sample Diluent: 1 x 20 mL
  • Detector Antibody Diluent: 1 x 12 mL
  • Conjugate Diluent: 1 x 12 mL
  • 25X Wash Buffer: 1 x 30 mL
  • TMB Substrate: 1 x 10 mL
  • Stop Solution: 1 x 10 mL
• Additional Information: Function: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.
  Subcellular Location: Isoform 5 Cytoplasm Nucleus Nucleus Nucleolus Predominantly nuclear but can shuttle between nucleus and cytoplasm. TNPO1 can mediate its nuclear import whereas XPO1 can mediate its nuclear export.
  Unigene: Hs.12341
  SMR: P55265
  String: 9606.ENSP00000357459
  KEGG: hsa:103
  MIM: 127400
  Pfam: PF02137
• Reconstitution and Storage: Store as indicated in product manual.
• Sensitivity: 0.182ng/mL
• Specificity: Natural and recombinant Human Double-stranded RNA-specific adenosine deaminase
• Assay Info: Assay Methodology: Quantitative Sandwich ELISA

Target Info

• Gene Symbol: ADAR
• Gene Full Name: adenosine deaminase RNA specific
• Alias Symbols: 136 kDa double-stranded RNA-binding protein;ADAR1;adenosine deaminase acting on RNA 1-A;AGS6;double-stranded RNA-specific adenosine deaminase;DRADA;DSH;DSRAD;dsRNA adenosine deaminase;dsRNA adeonosine deaminase;G1P1;IFI4;IFI-4;interferon-induced protein 4;interferon-inducible protein 4;K88DSRBP;P136.
• NCBI Gene Id: 103
• Protein Name: P55265
• Description of Target: Double-stranded RNA-specific adenosine deaminase
• Uniprot ID: https://www.uniprot.org/uniprot/P55265
• Protein Accession #: NP_001020278.1
• Nucleotide Accession #: NM_001025107.2